Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses changes in drug development and clinical trials at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He explains how hurdles for testing drugs from different companies are disappearing, allowing combination therapies to be trialed. Prof. Younes also discusses how the use of mechanism-based approaches could address the 90% failure rate in the pharmaceutical industry and result in lower costs for future treatments.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates